ciltacabtagene autoleucel
J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
Johnson & Johnson announces change in senior leadership role
Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine
Johnson & Johnson commits $5.5bn to end remaining talc litigation
The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis
Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes
Legend Biotech appoints new group of scientific advisors
The company is focused on CAR-T cell therapy to treat multiple myeloma
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
J&J’s nipocalimab gets FDA Fast Track designation for lupus
The autoimmune disease affects approximately three to five million people globally
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer
Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people